Core Viewpoint - The announcement by Xuan Bamboo Biotech-B (02575) regarding the inclusion of its innovative drug Pirlosil (brand name: Xuan Yuening) in the 2025 National Basic Medical Insurance Directory is a significant development that will enhance the drug's affordability and accessibility for patients, positively impacting the company's long-term operational growth [1] Group 1 - The innovative drug Pirlosil has been included in the 2025 National Basic Medical Insurance Directory, which will be officially implemented on January 1, 2026 [1] - This inclusion is expected to facilitate the market promotion and sales growth of Xuan Yuening, benefiting the company's long-term development [1] - The company plans to actively cooperate in the implementation of the medical insurance policy, continue to promote hospital access, expand core markets, and increase market coverage to enhance patient accessibility to the medication [1]
轩竹生物-B(02575)：创新药轩悦宁®首次纳入2025国家基本医保目录